• 1 南方醫(yī)科大學(xué)研究生學(xué)院（廣州，510515）;;
  • 2 廣州軍區(qū)廣州總醫(yī)院整形外科 全軍熱區(qū)創(chuàng)傷救治與組織修復(fù)重點實驗室;;
  • 3 暨南大學(xué)附屬第一醫(yī)院整形外科 組織再生教育部重點實驗室;

目的 阿片肽與增生性瘢痕患者感覺異常有關(guān)，通過比較β- 內(nèi)啡肽在人正常皮膚與增生性瘢痕組織中的表達(dá)情況，探討其在增生性瘢痕感覺異常發(fā)生、發(fā)展 中所起作用。 方法 取42 例增生性瘢痕患者自愿捐贈的增生性瘢痕組織；男15 例，女27 例；年齡16 ～ 50 歲，平均32.6 歲；瘢痕形成時間1 ～ 20 年，平均4.5 年。根據(jù)患者感覺情況，將瘢痕組織分為3 組，無痛癢組（n=20）、單純癢組（n=14）及痛癢組（n=8）。另取行植皮手術(shù)患者自愿捐贈的正常皮膚組織5 例作為正常對照組，男3 例，女2 例；年齡15 ～ 37 歲，平均24.6 歲。采用免疫熒光染色觀察β- 內(nèi)啡肽定位情況，ELISA 法檢測組織中β- 內(nèi)啡肽含量。 結(jié)果 各組組織中均可見β- 內(nèi)啡肽表達(dá)，主要位于真皮層周圍神經(jīng)末梢、成纖維細(xì)胞和單核樣細(xì)胞；其中單純癢組和痛癢組β- 內(nèi)啡肽表達(dá)明顯強(qiáng)于無痛癢組與正常對照組。無痛癢組、單純癢組、痛癢組及正常對照組組織β- 內(nèi)啡肽含量分別為（617.401 ± 97.518）、（739.543 ± 94.149）、（623.294 ± 149.613）、（319.734 ± 85.301）pg/ mL，其中無痛癢組、單純癢組及痛癢組β- 內(nèi)啡肽含量均顯著高于正常皮膚組（P  lt; 0.05），單純癢組高于無痛癢組及痛癢組（P  lt; 0.05），無痛癢組與痛癢組間差異無統(tǒng)計學(xué)意義（P  gt; 0.05）。 結(jié)論 增生性瘢痕中β- 內(nèi)啡肽的高表達(dá)，可能與其瘙癢發(fā)生有關(guān)。

引用本文： 朱江婷,程飚,劉宏偉,唐建兵,項曉飛,彭艷. β- 內(nèi)啡肽在增生性瘢痕組織中的表達(dá)及其與瘢痕瘙癢關(guān)系的研究. 中國修復(fù)重建外科雜志, 2012, 26(6): 731-734. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國修復(fù)重建外科雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Profyris C, Tziotzios C, Do Vale I, et al. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol, 2012, 66(1): 1-10.
2. Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses, 2008, 71(1): 32-38.
3. Pitzer GB, Patel KG. Proper care of early wounds to optimize healing and prevent complications. Facial Plast Surg Clin North Am, 2011, 19(3): 491-504.
4. Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011, 17(1-2): 113-125.
5. 程飚, 劉宏偉, 李勤, 等. β-內(nèi)啡肽與μ-阿片受體在正常皮膚與增生性瘢痕組織中的分布特征與生物學(xué)意義. 中華整形外科雜志, 2008, 24(5): 343-346.
6. 葉巧園, 樊翌明. P物質(zhì)、蛋白酶、阿片樣肽3種非組胺依賴性瘙癢介質(zhì)的研究進(jìn)展. 廣東醫(yī)學(xué)院學(xué)報, 2008, 26(5): 553-556.
7. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, et al. Opioids and the skin—where do we stand? Exp Dermatol, 2009, 18(5): 424-430.
8. 劉莉萍, 范衛(wèi)新. β-內(nèi)啡肽在皮膚中的作用. 臨床皮膚科雜志, 2006, 35(3): 192-193.
9. Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology, 2004, 209(3): 183-189.
10. Cheng B, Liu HW, Fu XB, et al. Update on pruritic mechanisms of hypertrophic scars in postburn patients: the potential role of opioids and their receptors. J Burn Care Res, 2011, 32(4): e118-125.
11. Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol, 2008, 158(1): 95-100.
12. Nelson RD. Postburn itch//Yosipovitch G, Greaves MW, Fleischer AB, et al. Itch: basic mechanism and therapy. New York: Marcel Dekker, 2004: 247-254.
13. Forbes-Duchart L, Cooper J, Nedelec B, et al. Burn therapists’ opinion on the application and essential characteristics of a burn scar outcome measure. J Burn Care Res, 2009, 30(5): 792-800.
14. Bigliardi-Qi M, Lipp B, Sumanovski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology, 2005, 210(2): 91-99.
15. Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol, 2011, 165(2): 277-284.
16. Cheng B, Liu HW, Fu XB, et al. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol, 2008, 158(4): 713-720.
17. Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci, 2006, 7(7): 535-547.
18. Goutos I. Burns pruritus—a study of current practices in the UK. Burns, 2010, 36(1): 42-48.
19. Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil, 2008, 22(4): 263-268.
  1. 1. Profyris C, Tziotzios C, Do Vale I, et al. Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics Part I. The molecular basis of scar formation. J Am Acad Dermatol, 2012, 66(1): 1-10.
  2. 2. Akaishi S, Ogawa R, Hyakusoku H. Keloid and hypertrophic scar: neurogenic inflammation hypotheses. Med Hypotheses, 2008, 71(1): 32-38.
  3. 3. Pitzer GB, Patel KG. Proper care of early wounds to optimize healing and prevent complications. Facial Plast Surg Clin North Am, 2011, 19(3): 491-504.
  4. 4. Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med, 2011, 17(1-2): 113-125.
  5. 5. 程飚, 劉宏偉, 李勤, 等. β-內(nèi)啡肽與μ-阿片受體在正常皮膚與增生性瘢痕組織中的分布特征與生物學(xué)意義. 中華整形外科雜志, 2008, 24(5): 343-346.
  6. 6. 葉巧園, 樊翌明. P物質(zhì)、蛋白酶、阿片樣肽3種非組胺依賴性瘙癢介質(zhì)的研究進(jìn)展. 廣東醫(yī)學(xué)院學(xué)報, 2008, 26(5): 553-556.
  7. 7. Bigliardi PL, Tobin DJ, Gaveriaux-Ruff C, et al. Opioids and the skin—where do we stand? Exp Dermatol, 2009, 18(5): 424-430.
  8. 8. 劉莉萍, 范衛(wèi)新. β-內(nèi)啡肽在皮膚中的作用. 臨床皮膚科雜志, 2006, 35(3): 192-193.
  9. 9. Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology, 2004, 209(3): 183-189.
  10. 10. Cheng B, Liu HW, Fu XB, et al. Update on pruritic mechanisms of hypertrophic scars in postburn patients: the potential role of opioids and their receptors. J Burn Care Res, 2011, 32(4): e118-125.
  11. 11. Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol, 2008, 158(1): 95-100.
  12. 12. Nelson RD. Postburn itch//Yosipovitch G, Greaves MW, Fleischer AB, et al. Itch: basic mechanism and therapy. New York: Marcel Dekker, 2004: 247-254.
  13. 13. Forbes-Duchart L, Cooper J, Nedelec B, et al. Burn therapists’ opinion on the application and essential characteristics of a burn scar outcome measure. J Burn Care Res, 2009, 30(5): 792-800.
  14. 14. Bigliardi-Qi M, Lipp B, Sumanovski LT, et al. Changes of epidermal mu-opiate receptor expression and nerve endings in chronic atopic dermatitis. Dermatology, 2005, 210(2): 91-99.
  15. 15. Taneda K, Tominaga M, Negi O, et al. Evaluation of epidermal nerve density and opioid receptor levels in psoriatic itch. Br J Dermatol, 2011, 165(2): 277-284.
  16. 16. Cheng B, Liu HW, Fu XB, et al. Coexistence and upregulation of three types of opioid receptors, mu, delta and kappa, in human hypertrophic scars. Br J Dermatol, 2008, 158(4): 713-720.
  17. 17. Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci, 2006, 7(7): 535-547.
  18. 18. Goutos I. Burns pruritus—a study of current practices in the UK. Burns, 2010, 36(1): 42-48.
  19. 19. Baker RA, Zeller RA, Klein RL, et al. Burn wound itch control using H1 and H2 antagonists. J Burn Care Rehabil, 2008, 22(4): 263-268.